Involvement of PKR in Alzheimer's Disease*Corresponding Author: Jacques Hugon, Memory Centre, Saint Louis Lariboisiere Fernand Widal Hospital APHP, University Paris Diderot Paris, France, Tel: 33 1 40054313, Email: [email protected]
Received Date: Mar 10, 2014 / Accepted Date: Jun 30, 2014 / Published Date: Jul 30, 2014
Citation: Hugon J, Mouton-Liger F, Dumurgier J, Lapalus P, Prevot M, et al. (2014) Involvement of PKR in Alzheimer’s Disease. J Alzheimers Dis Parkinsonism 4:154.DOI: 10.4172/2161-0460.1000154
Copyright: © 2014 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Alzheimer’s disease (AD) is characterized by memory troubles followed by aphasia apraxia and agnosia associated with behavioral disturbances. Neuropathological lesions include senile plaques formed by Aβ peptide, neurofibrillary tangles made of hyperphosphorylated tau and neuronal loss. The cause of AD is unknown but Aβ peptide could be responsible for neuronal degeneration. PKR is a stress and pro-apoptotic kinase that controls protein translation via the phosphorylation of the eukariotic initiation factor 2α (eIF2α). Activated PKR accumulates in affected neurons in AD brains and the phosphorylation of PKR can be induced by Aβ peptide. We have found increased levels of PKR in the cerebrospinal fluid of AD patients and PKR level is a good predictor of the cognitive decline. In addition PKR can modulate the levels of BACE1, an APP cleaving enzyme, and can influence tau phosphorylation. Altogether, PKR represents a potential new biomarker and a valid new therapeutic target for neuroprotection in AD.